Some good stuff coming in future!
$Biomea Fusion(BMEA.US$ Demonstrated durable HbA1c lowering in the escalation portion of ongoing
Phase II study in type 2 diabetes (COVALENT-111), with 84% of all
patients showing a reduction of HbA1c after 4 weeks dosing and 74% after
another 8 weeks off-treatment period
-- Expansion portion of COVALENT-111 cleared and actively enrolling in the
U.S. and Canada; expected to enroll approximately 200 adults with type 2
diabetes
-- Investigational new drug (IND) application cleared for Phase II clinical
trial of BMF-219 in type 1 diabetes (COVALENT-112); enrollment of 150
adults with type 1 diabetes anticipated to begin in Q4 2023
-- Dosed first relapsed/refractory AML patient with BMF-500, Biomea's novel
third generation investigational oral covalent inhibitor of FMS-like
tyrosine kinase 3 (FLT3)
-- Reported initial topline data of BMF-219 in ongoing Phase I clinical
trial (COVALENT-101), showing 2 complete responses (CRs) out of 5
relapsed/refractory AML patients with menin-dependent mutations at Dose
Level 4, with encouraging tolerability and safety data
-- Announced the appointment of Juan Pablo Frías, M.D., a prominent
diabetes clinical development expert as Chief Medical Officer to oversee
Biomea's progressing clinical development of novel covalent menin
inhibitor BMF-219 in type 2 and type 1 diabetes![]()
Phase II study in type 2 diabetes (COVALENT-111), with 84% of all
patients showing a reduction of HbA1c after 4 weeks dosing and 74% after
another 8 weeks off-treatment period
-- Expansion portion of COVALENT-111 cleared and actively enrolling in the
U.S. and Canada; expected to enroll approximately 200 adults with type 2
diabetes
-- Investigational new drug (IND) application cleared for Phase II clinical
trial of BMF-219 in type 1 diabetes (COVALENT-112); enrollment of 150
adults with type 1 diabetes anticipated to begin in Q4 2023
-- Dosed first relapsed/refractory AML patient with BMF-500, Biomea's novel
third generation investigational oral covalent inhibitor of FMS-like
tyrosine kinase 3 (FLT3)
-- Reported initial topline data of BMF-219 in ongoing Phase I clinical
trial (COVALENT-101), showing 2 complete responses (CRs) out of 5
relapsed/refractory AML patients with menin-dependent mutations at Dose
Level 4, with encouraging tolerability and safety data
-- Announced the appointment of Juan Pablo Frías, M.D., a prominent
diabetes clinical development expert as Chief Medical Officer to oversee
Biomea's progressing clinical development of novel covalent menin
inhibitor BMF-219 in type 2 and type 1 diabetes
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
